Adage Capital Partners
AMAM

Adage Capital Partners’s Ambrx Biopharma Inc AMAM Stock Holding History

Adage Capital Partners’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,027,291
Closed -$2.33M – 1026
2022
Q4 		$2.33M Sell
1,027,291
-1,000,000
-49% -$1.14M 0.01% 804
2022
Q3 		$2.19M Hold
2,027,291
– – 0.01% 849
2022
Q2 		$5.37M Hold
2,027,291
– – 0.01% 790
2022
Q1 		$8.35M Buy
2,027,291
+103,591
+5% +$530K 0.02% 743
2021
Q4 		$17.4M Buy
1,923,700
+96,408
+5% +$1.08M 0.03% 523
2021
Q3 		$24.7M Hold
1,827,292
– – 0.05% 380
2021
Q2 		$35.8M Buy
+1,827,292
New +$31.1M 0.07% 292

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Adage Capital Partners's AMAM Position: Q1 2023 in Review

Adage Capital Partners sold out of Ambrx Biopharma Inc (AMAM) in Q1 2023, closing a stake of 1,027,291 shares — an estimated $2.33M sold.

Adage Capital Partners first reported a position in AMAM in Q2 2021 and held it in 7 quarters. The position peaked at $35.8M in Q2 2021. 30 funds tracked by Wall St. Rank hold AMAM as of Q1 2023.

  • Adage Capital Partners reported no remaining Ambrx Biopharma Inc position as of Q1 2023 after selling out during the quarter.
  • Adage Capital Partners sold 1,027,291 Ambrx Biopharma Inc shares in Q1 2023, an estimated $2.33M.
  • Adage Capital Partners first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 7 quarters.
  • Adage Capital Partners's Ambrx Biopharma Inc position peaked at $35.8M in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2023.

Based on Adage Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.